Combination Treatment Migraine Study
Ages
Location
Compensation
Combination Treatment Migraine Trials in Columbus
Centricity Research is currently participating in a combination treatment migraine study at our Columbus, Ohio location. A proportion of individuals receiving preventive monotherapy for migraine may continue to experience migraine attacks and migraine-related disability. Atogepant has demonstrated effectiveness in significantly reducing the number of migraine and headache days in patients with episodic migraine. Ubrogepant has been approved by the FDA for the acute treatment of migraine with or without aura in adults.
Combination Treatment Migraine Clinical Trial
The purpose of this study is to evaluate the safety and tolerability of the combined use of ubrogepant 100 mg for the acute treatment of breakthrough migraine headaches in people taking atogepant 60 mg once a day for preventive treatment of migraine. You maybe be eligible to participate in this study if you:
- Are 18 to 80 years of age
- Have experienced migraines for 1 year or more, starting before age 50
- Have had migraines 4-14 days per month in each of the last 3 months
Ready to Volunteer?
Volunteer today to see if you qualify for our combination treatment migraine study. Qualified volunteers may be compensated for time and travel.